http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2618448-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22fa731cbdf84920f54a5b15a81554f7 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
filingDate | 2015-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d45aeb09617376a078202ebaecc7906e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685767535910f2d8dbad47234839a5b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0ce964175c2ea8a5846e915fb2e2fa5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e98661318cae5b3ef8a276bbad2c872a |
publicationDate | 2017-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2618448-C1 |
titleOfInvention | Method for adverse cardiac events risk assessment after percutaneous coronary intervention |
abstract | FIELD: medicine. n SUBSTANCE: presence or absence of diabetes is established, platelet aggregation, initial level of plasminogen-1 activator inhibitor and the degree of Willebrand factor activity in blood plasma is determined prior to surgery, the values are evaluated in points. According to the total value of the indices, the risk of adverse cardiac events for the patient under study is assessed. In case of the total score equal to or more than 2 - a high risk of adverse cardiac events after percutaneous coronary intervention is established. n EFFECT: method can reliably assess the risk of adverse events after percutaneous coronary intervention for patients with stable coronary heart disease. n 1 tbl, 3 ex |
priorityDate | 2015-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.